Search results for Pembrolizumab Biosimilar – Anti-PD1 mAb – Research Grade

Pembrolizumab Biosimilar – Anti-PD1 mAb – Research Grade, ProteoGenix, PX-TA1007

Description of Pembrolizumab Biosimilar - Anti-PD1 mAb - Research Grade General information about Pembrolizumab Pembrolizumab is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body’s immune cells and some cancer cells, known as PD-1/PD-L1. This product is for research use only.